Evaluation of the total distribution volume of 18F-FBPA in normal tissues of healthy volunteers by non-compartmental kinetic modeling

Objective Boron neutron capture therapy (BNCT) is a noninvasive radiation therapy method for cancer treatment. In BNCT, 4-borono-2-[ 18 F]-fluoro-L-phenylalanine ( 18 F-FBPA) PET has been employed to estimate 10 B accumulation in target tumors and normal tissues if 10 B borono-L-phenylalanine ( 10 B...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of nuclear medicine 2020-03, Vol.34 (3), p.155-162
Hauptverfasser: Romanov, Victor, Isohashi, Kayako, Alobthani, Galal, Beshr, Rouaa, Horitsugi, Genki, Kanai, Yasukazu, Naka, Sadahiro, Watabe, Tadashi, Shimosegawa, Eku, Hatazawa, Jun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective Boron neutron capture therapy (BNCT) is a noninvasive radiation therapy method for cancer treatment. In BNCT, 4-borono-2-[ 18 F]-fluoro-L-phenylalanine ( 18 F-FBPA) PET has been employed to estimate 10 B accumulation in target tumors and normal tissues if 10 B borono-L-phenylalanine ( 10 B-BPA) is used as a boron carrier. The purpose of the current study was to evaluate the total distribution volume (Vt) of 18 F-FBPA in normal organs of healthy volunteers by kinetic analysis and to estimate boron concentration in normal organs for the therapeutic dose of 10 B-BPA using obtained Vt values. Methods Six healthy volunteers were injected with 18 F-FBPA (3–5 MBq/kg), and 7 PET-CT scans were performed subsequently. 18 F-FBPA radioactivity in whole blood and plasma was measured before, and eight times after the injection. PET images were analyzed by PMOD software. Twelve volumetric regions of interest including the brain, heart, right lung, spleen, liver, parotid salivary glands, esophagus, stomach, pancreas, intestines, and bone marrow were drawn manually for each subject and analyzed with the Logan plot and two Ichise multilinear analyses (MA1 and MA2). The better model was defined by several goodness-of-fit parameters and residual distribution. After Vt values had been derived, boron concentration was estimated in ppm for the 10 B-BPA-fructose ( 10 B-BPA-fr) dose 30 g 1 and 2 h post-injection using Vt and interpolated plasma activity data. Results The Ichise MA2 model showed the best fit among all models. Akaike Information Criterion (AIC) was the lowest for the Ichise’s MA2 in all regions (mean AIC value − 14.0) comparing to the other models (Logan plot mean AIC 31.4; Ichise MA1 model mean AIC − 4.2). Mean Vt values of the Ichise MA2 model ranged from 0.94 ± 0.14 ml/ml in the pancreas to 0.16 ± 0.02 ml/ml in the right lung. Estimated boron concentration for 10 B-BPA-fr had the highest value in the pancreas (14.0 ± 1.9 ppm 1 h after, and 5.7 ± 1.7 ppm 2 h after the 18 F-FBPA administration) and the lowest value in the right lung (2.4 ± 0.3 ppm 1 h, and 1.0 ± 0.3 ppm 2 h post-injection). Conclusion The 10 B concentration in normal tissues was best estimated using Vt values of 18 F-FBPA with the Ichise multilinear analysis 2 (MA2). Trail registry The UMIN clinical trial number: UMIN000022850.
ISSN:0914-7187
1864-6433
DOI:10.1007/s12149-019-01427-9